$32.02
2.14% today
Nasdaq, Feb 28, 05:17 pm CET
ISIN
US4622221004
Symbol
IONS
Sector
Industry

Ionis Pharmaceuticals, Inc. Stock price

$31.35
-2.70 7.93% 1M
-17.00 35.16% 6M
-3.61 10.33% YTD
-16.06 33.87% 1Y
-2.03 6.08% 3Y
-21.94 41.17% 5Y
-37.21 54.27% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.41 1.29%
ISIN
US4622221004
Symbol
IONS
Sector
Industry

Key metrics

Market capitalization $4.98b
Enterprise Value $4.64b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.58
P/S ratio (TTM) P/S ratio 7.06
P/B ratio (TTM) P/B ratio 8.41
Revenue growth (TTM) Revenue growth -10.48%
Revenue (TTM) Revenue $705.56m
EBIT (operating result TTM) EBIT $-474.26m
Free Cash Flow (TTM) Free Cash Flow $-546.23m
Cash position $2.30b
EPS (TTM) EPS $-3.04
P/E forward negative
P/S forward 7.58
EV/Sales forward 7.05
Short interest 8.96%
Show more

Is Ionis Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Ionis Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

25 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

17x Buy
68%
7x Hold
28%
1x Sell
4%

Analyst Opinions

25 Analysts have issued a Ionis Pharmaceuticals, Inc. forecast:

Buy
68%
Hold
28%
Sell
4%

Financial data from Ionis Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
706 706
10% 10%
100%
- Direct Costs 33 33
6% 6%
5%
672 672
11% 11%
95%
- Selling and Administrative Expenses 223 223
19% 19%
32%
- Research and Development Expense 901 901
0% 0%
128%
-452 -452
37% 37%
-64%
- Depreciation and Amortization 22 22
2% 2%
3%
EBIT (Operating Income) EBIT -474 -474
34% 34%
-67%
Net Profit -454 -454
24% 24%
-64%

In millions USD.

Don't miss a Thing! We will send you all news about Ionis Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ionis Pharmaceuticals, Inc. Stock News

Neutral
Business Wire
3 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will participate in fireside chats at the following investor conferences: Raymond James 46th Annual Institutional Investors Conference on Tuesday, March 4, 2025 TD Cowen 45th Annual Health Care Conference on Tuesday, March 4, 2025 Leerink Partners Global Healthcare Conference 2025 on Tu...
Neutral
Business Wire
8 days ago
CARLSBAD, Calif.--(BUSINESS WIRE)--Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that it will present additional data from the pivotal Phase 3 OASIS and OASISplus studies, as well as three year data from the Phase 2 open-label extension (OLE) study of donidalorsen, the company's investigational RNA-targeted prophylactic medicine for hereditary angioedema (HAE). Results will be pres...
Neutral
Seeking Alpha
9 days ago
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS ) Q4 2024 Earnings Conference Call February 19, 2025 11:30 AM ET Company Participants Wade Walke - Senior Vice President of Investor Relations Brett Monia - Chief Executive Officer Kyle Jenne - Chief Global Product Strategy Officer Richard Geary - Chief Development Officer Elizabeth Hougen - Chief Financial Officer Eugene Schneider - Chief Clinical Devel...
More Ionis Pharmaceuticals, Inc. News

Company Profile

Ionis Pharmaceuticals, Inc. engages in the development and commercialization of human therapeutic drugs using antisense technology. It operates through the Ionis Core and Akcea Therapeutics segments. The Ionis Core segment exploits a novel drug discovery platform to generate a pipeline of drugs. The Akcea Therapeutics segment develops and commercializes drugs for cardiometabolic diseases. The company was founded by Stanley T. Crooke, David J. Ecker, Christopher K. Mirabelli and Brett P. Monia in 1989 and is headquartered in Carlsbad, CA.

Head office United States
CEO Brett Monia
Employees 1,069
Founded 1989
Website www.ionis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today